Table 1.
Clinical-pathological characteristics of the discovery cohort
| Characteristic | Number of patients (%) |
|---|---|
| Total patients with evaluable tumors | 53 |
| Treatment | |
| Nivolumab | 45 (86) |
| Pembrolizumab | 6 (6) |
| Atezolizumab | 4 (8) |
| Gender | |
| Female | 24 (45) |
| Male | 29 (55) |
| Age | |
| <70yo | 23 (44) |
| ≥70yo | 30 (57) |
| Performance status | |
| 0-1 | 46 (87) |
| >1 | 7 (13) |
| Smoking | |
| Ever smoker | 46 (87) |
| Never smoker | 7 (13) |
| Histology | |
| Adenocarcinoma | 38 (72) |
| Squamous-cell carcinoma | 12 (23) |
| Large-cell carcinoma | 3 (5) |
| Type and site of tumor specimen | |
| Lung primary | 37 (70) |
| Non-lymph node metastasis | 7 (13) |
| Lymph node metastasis | 9 (17) |
| Stage | |
| III | 1 (2) |
| M1a | 13 (24) |
| M1b | 9 (17) |
| M1c | 29 (55) |
| Liver metastasis | |
| Yes | 11 (21) |
| No | 41 (77) |
| Missing | 1 |
| Mutation status | |
| EGFR | 5 (9) |
| KRAS | 15 (28) |
| Others | 5 (9) |
| Wild-type | 28 (53) |
| Derived neutrophil to lymphocyte ratio (dNLR) | |
| ≤3 | 35 (66) |
| >3 | 16 (30) |
| Missing | 2 |
| Lung immune prognostic index (LIPI) score | |
| Good | 22 (41) |
| Intermediate | 19 (36) |
| Poor | 3 (6) |
| Missing | 9 |
| Prior systemic therapies for advanced disease | |
| 0 | 9 (17) |
| 1 | 27 (51) |
| >1 | 17 (32) |
| Best response to immunotherapy | |
| Partial response | 6 (11) |
| Stable disease | 18 (34) |
| Progressive disease | 27 (51) |
| Not evaluable | 2 |
| Benefit from immunotherapy* | |
| Clinical benefit (CB) | 16 (30) |
| Non-clinical benefit (NCB) | 35 (66) |
| Not evaluable | 2 |
*
We defined clinical benefit (CB) as having experienced partial response or stable disease lasting ≥ 6 months as best response, whereas non-clinical benefit (NCB) was defined as primary progressive disease or stable disease lasting < 6 months.